28. A free-flowing, cohesive powder comprising a compound according to any one of claims 1 to 12 and at least one diluent suitable for dry compression and optionally one or more other excipients, said powder being capable of being compressed into a solid dosage form.

29. A process as claimed in claim 14 for the manufacture of a pharmaceutical composition, which process comprises dry compression of an intimate powder mixture comprising the compound according to any one of claims 1 to 12 with at least one diluent suitable for dry compression and optionally one or more other excipients.

30. A process according to claim 29, wherein the process comprises a direct compression process wherein said compound, at least one diluent, and optional excipients are blended together in solid particulate form to create said intimate mixture and then compressed using a tablet machine.

31. A process according to claim 30, wherein said at least one diluent is selected from microcrystalline cellulose, lactose, mannitol, calcium salts such as, calcium phosphate dibasic, calcium sulphate, calcium carbonate, and sugars such as lactose, sucrose, dextrose and maltodextrin.

32. A process according to claim 30, wherein said at least one diluent is a granulated product prepared by moist granulation of one or more excipients.

33. A process according to claim 32, comprising a step of wet massing one or more excipients using a granulating fluid, and drying to form said granulated product.

34. A process according to claim 29, wherein the process comprises a dry granulation process wherein said compound, at least one diluent, and optional excipients are formed into a compressed mass, milled and then compressed using a tablet machine.

35. A process according to any one of claims 28 to 33 further comprising the step of applying a film coating to the resultant tablets.

36. A compound or composition according to any one of claims 1 to 12 or 15 to 27 for use in a method of treatment or prophylaxis of the human or animal body by therapy.

~~37. A compound or composition according to any one of claims 1 to 12 or 15 to 27 for use in a method of treatment or prophylaxis of a disease of protein aggregation.~~

38. A compound or composition according to any one of claims 1 to 12 or 15 to 27 for use in a method of treatment or prophylaxis of a tauopathy.

39. A compound or composition according to any one of claims 1 to 12 or 15 to 27 for use in a method of treatment or prophylaxis of Alzheimer's disease (AD), Pick's disease, progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), FTD with parkinsonism linked to chromosome 17 (FTDP 17), frontotemporal lobar degeneration (FTLD) syndromes; disinhibition-dementia-parkinsonism-amyotrophy complex (DDPAC), pallido-ponto-nigral degeneration (PPND), Guam-ALS syndrome, pallido nigro luysian degeneration (PNLD), cortico-basal degeneration (CBD), dementia with argyrophilic grains (AgD), dementia pugilistica (DP) or chronic traumatic encephalopathy (CTE), Down's syndrome (DS), dementia with Lewy bodies (DLB), subacute sclerosing panencephalitis (SSPE), MCI, Niemann-Pick disease, type C (NPC), Sanfilippo syndrome type B (or mucopolysaccharidosis III B (MPS III B)), or myotonic dystrophies (DM), DM1 or DM2.

40. A compound or composition according to any one of claims 1 to 12 or 15 to 27 for use in a method of treatment or prophylaxis of Alzheimer's disease.

41. A compound or composition according to any one of claims 1 to 12 or 15 to 27 for use in a method of treatment or prophylaxis of Parkinson's disease.

42. A compound or composition according to any one of claims 1 to 12 or 15 to 27 for use in a method of treatment or prophylaxis of PSP, ALS, or FTLD.

43. A compound or composition according to any one of claims 1 to 12 for use in a method of treatment or prophylaxis of Huntington's disease or other polyglutamine disorder, such as spinal bulbar muscular atrophy (Kennedy disease), dentatorubropallidoluysian atrophy or spinocerebellar ataxias.

44. A compound or composition according to any one of claims 1 to 12 or 15 to 27 for use in a method of treatment or prophylaxis of skin cancer or melanoma; or a viral, bacterial or protozoal disease condition.

45. A compound or composition for use according to claim 44 wherein the viral, bacterial or protozoal disease is selected from Hepatitis C, HIV, West Nile Virus (WNV) and malaria.

~~37~~46. Use of a compound or composition according to any one of claims 1 to 12 or 15 to 27 in the manufacture of a medicament for use in the treatment or prophylaxis of a disease of protein aggregation.

38. Use of a compound or composition according to any one of claims 1 to 12 or 15 to 27 in the manufacture of a medicament for use in the treatment or prophylaxis of a TDP-43 proteinopathy.

~~39~~47. Use of a compound or composition according to any one of claims 1 to 12 or 15 to 27 in the manufacture of a medicament for use in the treatment or prophylaxis of a tauopathy.

~~40~~48. Use of a compound or composition according to any one of claims 1 to 12 or 15 to 27 in the manufacture of a medicament for use in the treatment or prophylaxis of Alzheimer's disease (AD), Pick's disease, progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), FTD with parkinsonism linked to chromosome 17 ~~(FTDP-17)~~, frontotemporal lobar degeneration (FTLD) syndromes; disinhibition-dementia-parkinsonism-amyotrophy complex ~~(DDPAC)~~, pallido-ponto-nigral degeneration ~~(PPND)~~, Guam-ALS syndrome, pallido nigro luysian degeneration ~~(PNLD)~~, cortico-basal degeneration ~~(CBD)~~, dementia with argyrophilic grains ~~(AgD)~~, dementia pugilistica ~~(DP)~~ or chronic traumatic encephalopathy ~~(CTE)~~, Down's syndrome ~~(DS)~~, dementia with Lewy bodies ~~(DLB)~~, subacute sclerosing panencephalitis ~~(SSPE)~~, mild cognitive impairment~~MCI~~, Niemann-Pick disease, type C ~~(NPC)~~, Sanfilippo syndrome type B ~~(or mucopolysaccharidosis III B), or~~, myotonic dystrophies ~~(DM),~~ DM1 or DM2 or amyotrophic lateral sclerosis (ALS).

~~41~~49. Use of a compound or composition according to any one of claims 1 to 12 or 15 to 27 in the manufacture of a medicament for use in the treatment or prophylaxis of Alzheimer's disease.

~~42~~50 Use of a compound or composition according to any one of claims 1 to 12 or 15 to 27 in the manufacture of a medicament for use in the treatment or prophylaxis of Parkinson's disease.

~~43~~51 Use of a compound or composition according to any one of claims 1 to 12 or 15 to 27 in the manufacture of a medicament for use in the treatment or prophylaxis of PSP, ALS or FTLD.

~~44~~52. Use of a compound or composition according to any one of claims 1 to 12 or 15 to 27 in the manufacture of a medicament for use in the treatment or prophylaxis of a ~~Huntington's disease or other~~ polyglutamine disorder~~, such as spinal bulbar muscular atrophy (Kennedy disease), dentatorubropallidoluysian atrophy or spinocerebellar ataxias~~.

45. Use of a compound or composition according to claim 44 in the manufacture of a medicament for use in the treatment or prophylaxis of Huntington's disease, spinal bulbar muscular atrophy, dentatorubropallidoluysian atrophy or spinocerebellar ataxias.

46~~53~~. Use of a compound or composition according to any one of claims 1 to 12 or 15 to 27 in the manufacture of a medicament for use in the treatment or prophylaxis of skin cancer or melanoma; or a viral, bacterial or protozoal disease condition.

47~~54~~. Use according to claim 46~~53~~, wherein the viral, bacterial or protozoal disease is selected from Hepatitis C, HIV, West Nile Virus ~~(WNV)~~ and malaria.

~~55. A method of treatment or prophylaxis of a disease of protein aggregation in a subject comprising administering to said subject a prophylactically or therapeutically effective amount of a compound or composition according to any one of claims 1 to 12 or 15 to 27.~~

~~56. A method of treatment or prophylaxis of a tauopathy in a subject comprising administering to said subject a prophylactically or therapeutically effective amount of a compound or composition according to any one of claims 1 to 12 or 15 to 27.~~

~~57. A method of treatment or prophylaxis of Alzheimer's disease in a subject comprising administering to said subject a prophylactically or therapeutically effective amount of a compound or composition according to any one of claims 1 to 12 or 15 to 27.~~

~~58. A method of treatment or prophylaxis of Parkinson's disease in a subject comprising administering to said subject a prophylactically or therapeutically effective amount of a compound or composition according to any one of claims 1 to 12 or 15 to 27.~~

~~59. A method of treatment or prophylaxis of PSP, ALS or FTLD in a subject comprising administering to said subject a prophylactically or therapeutically effective amount of a compound or composition according to any one of claims 1 to 12 or 15 to 27.~~

~~60. A method of treatment or prophylaxis of Huntington's disease or other polyglutamine disorder, such as spinal bulbar muscular atrophy (Kennedy disease), dentatorubropallidoluysian atrophy or spinocerebellar ataxias in a subject comprising administering to said subject a prophylactically or therapeutically effective amount of a compound according to any one of claims 1 to 12 or 15 to 27.~~

~~61. A method of treatment or prophylaxis of skin cancer or melanoma; or a viral, bacterial or protozoal disease in a subject, comprising administering to said~~

~~subject a prophylactically or therapeutically effective amount of a compound or composition according to any one of claims 1 to 12 or 15 to 27.~~

~~62. A method according to claim 61, wherein the viral, bacterial or protozoal disease is selected from Hepatitis C, HIV, West Nile Virus (WNV) and malaria.~~

~~63~~. A method of reversing and/or inhibiting the aggregation of a protein comprising contacting the protein with an effective amount of a compound or composition according to any one of claims 1 to 12 or 15 to 27.

~~64. A method of reversing and/or inhibiting the aggregation of a protein in the brain of a mammal, which aggregation is associated with a disease state, the treatment comprising the step of administering to said mammal in need of said treatment, a prophylactically or therapeutically effective amount of a compound or composition according to any one of claims 1 to 12 or 15 to 27.~~

~~65~~. A method of inactivating a pathogen in a sample, comprising the steps of introducing a compound according to any one of claims 1 to 12 into the sample, and then exposing the sample to light.

~~66~~. A process for the preparation of a compound according to any one of claims 1 to 12 from a *N*-protected 3,7-diamino-10H-phenothiazine, comprising the steps of:

ring amino deprotection (DP); and

salt formation (SF).

~~67~~. A process according to claim ~~66~~, wherein the *N*-protected 3,7-diamino-10H-phenothiazine is a compound of formula (II):



(II)

wherein R^{Prot} is an amine protecting group and R^1, R^9, R^{3NA}, R^{3NB}, R^{7NA}, R^{7NB}, R^A and R^B are as previously defined.

~~68~~. A process according to claim ~~67~~, wherein R^{Prot} is acyl.

~~69~~. A process according to any one of claims ~~66~~ to ~~68~~, wherein ring amino deprotection (DP) and salt formation (SF) are performed simultaneously.

5470. A process according to claim 5369, wherein ring amino deprotection (DP) and salt formation (SF) comprise treatment of the *N*-protected 3,7-diamino-10H-phenothiazine with at least one sulfonic acid.

5571. A process according to claim 5470, wherein ring amino deprotection (DP) and salt formation (SF) comprise treatment of the *N*-protected 3,7-diamino-10H-phenothiazine with methanesulfonic acid and water, in an organic solvent, to produce the *bis*(methanesulfonate) salt.